Medivir Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Medivir wird ein Gewinn- und Umsatzwachstum von 37.9% bzw. 58.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 38.3% pro Jahr wachsen soll.

Wichtige Informationen

37.9%

Wachstumsrate der Gewinne

38.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	37.0%
Wachstumsrate der Einnahmen	58.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0GP7 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	10	-163	-204	-125	4
12/31/2025	52	-92	-170	-37	4
12/31/2024	32	-75	-45	-71	3
3/31/2024	8	-97	-79	-79	N/A
12/31/2023	8	-89	-60	-60	N/A
9/30/2023	6	-87	-80	-80	N/A
6/30/2023	6	-78	-79	-78	N/A
3/31/2023	4	-75	-78	-78	N/A
12/31/2022	4	-89	-102	-102	N/A
9/30/2022	23	-95	-83	-83	N/A
6/30/2022	23	-94	-83	-83	N/A
3/31/2022	23	-88	-87	-87	N/A
12/31/2021	32	-63	-49	-49	N/A
9/30/2021	3	-50	-47	-44	N/A
6/30/2021	19	-32	-44	-41	N/A
3/31/2021	23	-27	-46	-43	N/A
12/31/2020	20	-43	-61	-58	N/A
9/30/2020	30	-64	-81	-80	N/A
6/30/2020	14	-91	-98	-96	N/A
3/31/2020	14	-91	-110	-109	N/A
12/31/2019	9	-123	-150	-148	N/A
9/30/2019	21	-206	-196	-196	N/A
6/30/2019	23	-254	-244	-241	N/A
3/31/2019	21	-333	-293	-288	N/A
12/31/2018	24	-350	-325	-319	N/A
9/30/2018	15	-339	-345	-337	N/A
6/30/2018	17	-348	-328	-322	N/A
3/31/2018	23	-348	-329	-322	N/A
12/31/2017	37	-360	N/A	-358	N/A
9/30/2017	42	-379	N/A	-341	N/A
6/30/2017	63	-353	N/A	-315	N/A
3/31/2017	90	-320	N/A	-270	N/A
12/31/2016	93	-295	N/A	-182	N/A
9/30/2016	-16	-262	N/A	-108	N/A
6/30/2016	70	-218	N/A	4	N/A
3/31/2016	279	-95	N/A	106	N/A
12/31/2015	474	32	N/A	347	N/A
9/30/2015	950	268	N/A	855	N/A
6/30/2015	1,456	652	N/A	1,253	N/A
3/31/2015	1,775	916	N/A	1,277	N/A
12/31/2014	1,767	1,133	N/A	1,014	N/A
9/30/2014	1,537	1,005	N/A	580	N/A
6/30/2014	1,000	620	N/A	101	N/A
3/31/2014	476	229	N/A	4	N/A
12/31/2013	446	16	N/A	43	N/A
9/30/2013	348	-74	N/A	-82	N/A
6/30/2013	304	-119	N/A	-116	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0GP7 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 0GP7 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 0GP7 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 0GP7Die Einnahmen des Unternehmens (58.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.5% pro Jahr).

Hohe Wachstumseinnahmen: 0GP7Die Einnahmen des Unternehmens (58.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 0GP7 in 3 Jahren voraussichtlich hoch sein wird

Medivir Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Medivir Aktiebolag (publ) Approves Board Appointments

High number of new and inexperienced directors

Full year 2023 earnings released: kr1.48 loss per share (vs kr1.59 loss in FY 2022)

High number of new and inexperienced directors

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

High number of new and inexperienced directors

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.27 loss in 3Q 2022)

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

High number of new and inexperienced directors

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Medivir AB Announces Patent Application for Fostrox Approval in China

New major risk - Revenue size

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken